Fig. 5: Impact of GSK-3β-DN expression on seizure severity and neurodegeneration. | Cell Death & Disease

Fig. 5: Impact of GSK-3β-DN expression on seizure severity and neurodegeneration.

From: Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus

Fig. 5

a Schematic of transgenic strategy to overexpress GSK-3β-DN in forebrain neurons and representative immunostaining showing the expression of the reporter gene β-Gal in the hippocampus. Scale bar = 500 µm. b Graph and representative heatmap showing increased total seizure power of GSK-3β-DN mice when compared to wild-type (wt) mice during a 40 min recording period starting at intra-amygdala KA injection until lorazepam administration (mean ± s.d., *p < 0.05 by Student’s two-tailed t test, n = 9 (wt) and n = 7 (GSK-3β-DN)). c Graph and corresponding FjB stainings (×5 and ×20 lens) showing strongly increased neurodegeneration in the hippocampus of GSK-3β-DN mice when compared to wild-type (wt) mice 72 h following SE (mean ± s.d., *p < 0.05, **p < 0.01 and ***p < 0.001 by Student’s two-tailed t test, n = 12 (wt) and 6 (GSK-3-DN)). Scale bar = 500 µm for hippocampal overview and for hippocampal subfields

Back to article page